Ticker brief
AQST AQUESTIVE THERAPEUTICS INC
Consumer, Non-cyclical · Pharmaceuticals
last close
$4.00
1 day
-3.1%
14 days
-16.3%
mkt cap
·
signals 14d
6
authors 14d
5
crowd 14d
-1.2σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-14 → 2026-10-15 · now +0.08 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PrismMarketView | C | · | 2 | +0.40 |
| @PrismDM | A | -2.76 | 1 | +0.30 |
| @BioStocks | C | -1.77 | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | -0.35 |
| @TWFeditor | C | -1.36 | 1 | -0.35 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @TWFeditor | -0.35 | Notes AQST has not recovered to its 2025 highs. | -1.5% | tweet ↗ |
| 2026-10-15 | @PrismMarketView | +0.50 | FDA accepted AQST's NDA resubmission and set a March 2027 goal date. | -1.5% | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | -0.35 | The tweet lists large opening biotech moves and upcoming Phase 3 catalysts. | -1.5% | tweet ↗ |
| 2026-10-15 | @BioStocks | +0.50 | The FDA accepted AQST's Anaphylm NDA resubmission and set a March 16, 2027 PDUFA date. | -1.5% | tweet ↗ |
| 2026-10-14 | @PrismMarketView | +0.30 | Aquestive licensed exclusive US rights to Eton with a planned launch. | -13.2% | tweet ↗ |
| 2026-10-14 | @PrismDM | +0.30 | Aquestive licensed exclusive U.S. LIBERVANT rights to Eton, with an April 2027 launch expected. | -13.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.